Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
February 17 2022 - 7:08AM
InvestorsHub NewsWire
TORONTO, Canada -- February 17, 2022 -- InvestorsHub NewsWire
-- Mindset Pharma
Inc. (CSE:
MSET) (FSE: 9DF) (OTCQB:
MSSTF) ("Mindset" or the "Company"), a drug discovery
and development company focused on creating optimized and
patentable next-generation psychedelic medicines to treat
neurological and psychiatric disorders with unmet medical needs,
today announced that, under its Co-operative Psychedelics
Evaluation Platform ("COPE") program with InterVivo Solutions Inc.
("InterVivo"), the Company has identified new pharmacological
insights related to the mechanisms of action and bioavailability of
5-MeO-DMT and other first generation psychedelics. Specifically,
Mindset has further developed standard pharmacokinetics and drug
discrimination data and protocols across LSD, psilocybin,
5-MeO-DMT, and now psilocin.
Comparisons of psilocybin and 5-MeO-DMT benchmarking data have
revealed potential differences in the mechanism of action related
to the hallucinogenic experience of 5-MeO-DMT versus psilocybin.
Furthermore, data suggests that the oral bioavailability of
5-MeO-DMT increases at higher doses in rodents.
"In rodent drug discrimination studies, 5-HT2A antagonists
completely block the ability of rats to perceive psilocybin,
whereas the same antagonists do not completely block the effects of
5-MeO-DMT, suggesting that the perceptual experience of 5-MeO-DMT
is due not only to 5-HT2A receptor agonism," said Joseph Araujo,
Chief Scientific Officer of Mindset. "Pharmacokinetics studies also
show 5-MeO-DMT is not orally bioavailable at low doses, but at
higher doses, 5-MeO-DMT is bioavailable and its half-life is
prolonged, indicating that its metabolism is saturable. This
exemplifies the importance of studying a range of doses of
psychedelics for benchmarking purposes."
"Mindset is developing a spectrum of differentiated,
next-generation medical psychedelics with the goal of improving
several factors compared to first-generation psychedelic drugs,"
said James Lanthier, CEO of Mindset. "Thanks to this detailed
benchmarking data, we're better positioned to pre-clinically
evaluate and assess drug candidates, which are essential towards
reaching our treatment goals."
The COPE Program is a translational testing platform developed
in cooperation with InterVivo to introduce an industry standard
against which the performance and efficacy of breakthrough
psychedelic medicines are compared and assessed. Through this
platform, Mindset and InterVivo intend to establish the first
comprehensive psychedelics benchmark reference data set by
evaluating a broad range of psychedelic drugs through a proprietary
program of in vivo tests conducted at
InterVivo's facility. The COPE platform is anticipated to represent
an invaluable tool to guide the development of next-generation
psychedelic compounds and improve patentability and value of new
potential drug assets.
To watch a video of Mindset's CEO discussing the announcement in
greater detail, please visit: https://youtu.be/kS6Rc0BhIK4
About InterVivo Solutions Inc.
InterVivo Solutions is Canada's top neuroscience contract research
organization, offering translational research services with a focus
on next-generation neuroscience drug discovery. InterVivo and its
sister company, Transpharmation, offer a wide range of contract
services that are focused on discovery and development of
neurological and neuropsychiatric new chemical entities including
in vivo proof of concept, drug metabolism, pharmacokinetics and
early safety research studies for a global client base.
www.intervivo.com / www.transpharmation.co.uk
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company
focused on creating optimized and patentable next-generation
psychedelic medicines to treat neurological and psychiatric
disorders with unmet needs. Mindset was established in order to
develop next-generation pharmaceutical assets that leverage the
breakthrough therapeutic potential of psychedelic drugs. Mindset is
developing several novel families of next-generation psychedelic
compounds, as well as an innovative process to chemically
synthesize psilocybin in addition to its own proprietary compounds.
The company has a co-development agreement with the McQuade Center
for Strategic Research and Development, a member of the Otsuka
Pharmaceuticals family of companies, for its short-duration
compounds, Mindset Families 2 & 4.
For further information on Mindset, please visit our website
at www.mindsetpharma.com.
For more information, please contact:
Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585
Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com
Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094
Forward-Looking Information
This news release contains certain "forward-looking information"
within the meaning of applicable securities law. Forward looking
information is frequently characterized by words such as "plan",
"expect", "project", "intend", "believe", "anticipate", "estimate",
"may", "will", "would", "potential", "proposed" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions.
Forward-looking information is based on the opinions and estimates
of management at the date the information is provided and is
subject to a variety of risks and uncertainties and other factors
that could cause actual events or results to differ materially from
those projected in the forward-looking information. Additional
information regarding risks and uncertainties relating to the
Company's business are contained under the heading "Risk Factors"
in the Company's annual information form for the financial year
ended June 30, 2020 dated March 5, 2021. The forward-looking
information included in this news release is made as of the date of
this news release and the Company does not undertake an obligation
to publicly update such forward-looking information to reflect new
information, subsequent events or otherwise, except as required by
applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS
REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE.
Mindset Pharma (CSE:MSET)
Historical Stock Chart
From Oct 2024 to Nov 2024
Mindset Pharma (CSE:MSET)
Historical Stock Chart
From Nov 2023 to Nov 2024